icovamenib + semaglutide

icovamenib + semaglutide is an investigational combination regimen consisting of icovamenib (BMF-219), an oral, covalent small-molecule menin inhibitor, and semaglutide, an injectable glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Biomea Fusion in collaboration with the University of Leicester's Leicester Diabetes Centre, the combination is being evaluated to determine if adding icovamenib can enhance the weight-lowering effects of semaglutide while preserving lean muscle mass and supporting bone and metabolic health. The combination is currently in Phase II clinical development for obesity (or overweight with weight-related complications) in individuals without type 2 diabetes, evaluated within the multi-arm adaptive platform trial OPAL. It is also being investigated for type 2 diabetes, supported by preclinical studies demonstrating improved glycemic control, weight loss, and lean mass preservation compared to semaglutide alone.